19.15
+0.45(+2.41%)
Currency In USD
| Previous Close | 18.97 |
| Open | 18.82 |
| Day High | 19.95 |
| Day Low | 18.5 |
| 52-Week High | 65.8 |
| 52-Week Low | 2.62 |
| Volume | 331,887 |
| Average Volume | 372,661 |
| Market Cap | 118.45M |
| PE | -0.07 |
| EPS | -273.6 |
| Moving Average 50 Days | 31.74 |
| Moving Average 200 Days | 24.81 |
| Change | -0.27 |
If you invested $1000 in Vor Biopharma Inc. (VOR) since IPO date, it would be worth $498.67 as of November 10, 2025 at a share price of $18.7. Whereas If you bought $1000 worth of Vor Biopharma Inc. (VOR) shares 3 years ago, it would be worth $4,698.49 as of November 10, 2025 at a share price of $18.7.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
GlobeNewswire Inc.
Nov 08, 2025 4:45 PM GMT
Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with a favorable safety profile Telitacicept demonstrated a 55% reduction in 24-hour urine protein-to-creatin
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
GlobeNewswire Inc.
Nov 03, 2025 1:00 PM GMT
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Jeremy Sokolove, M.D., as Chief Medical Officer. Dr. Sokol
Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data
GlobeNewswire Inc.
Oct 29, 2025 3:01 PM GMT
Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms 100% of patients on telitacicept for 48 weeks achieved ≥2-point Myasthenia Gravis Activities of Daily Living (MG-ADL) improvement, with a m